$LXEO News
Last published 1w ago
- 1w agoLXEOLexeo Therapeutics to Present Multiple Oral and Poster Presentations at Key Scientific Conferences in NovemberGlobeNewswirePresentations at AHA to highlight Lexeo's cardiovascular gene therapy pipeline, including preclinical programs in desmoplakin and TNNI3 cardiomyopathies New LX2006 data to be presented at ICAR demonstrating cardiac
- 3w agoLXEOLexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACMGlobeNewswireNEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that it will host an
- 1mo agoLXEOLexeo Therapeutics to Participate in the Chardan Healthcare ConferenceGlobeNewswireNEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will
- 2mo agoLXEOLexeo Therapeutics to Participate in Upcoming Investor Conferences in SeptemberGlobeNewswireNEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO) a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that
- 3mo agoLXEOLexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational HighlightsGlobeNewswireFinalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027 Initiated SUNRISE-FA 2 with first patient enrolled
- 3mo agoLXEOLexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic CardiomyopathyGlobeNewswireRMAT designation granted based on recent interim clinical data from ongoing Phase I/II clinical trial evaluating LX2020 for PKP2-ACM LX2020 now holds RMAT, Orphan Drug and Fast Track designations by the FDA NEW YORK,
- 4mo agoLXEOLexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich AtaxiaGlobeNewswirePublished findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs of efficacy in Phase I/II studies SUNRISE-FA 2 pivotal study for LX2006 on track to initiate in Q2 2026 with topline
- 4mo agoLXEOLexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich AtaxiaGlobeNewswireSUNRISE-FA 2 study parameters include LVMI primary endpoint, 6-month topline efficacy analysis, inclusion criteria focused on abnormal baseline LVMI and open-label trial design BLA supportive manufacturing strategy
- 5mo agoLXEOLexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare ConferenceGlobeNewswireNEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that
- 6mo agoLXEOLexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational HighlightsGlobeNewswireSUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026; Awaiting final FDA feedback Multiple presentations highlighting progress across cardiac genetic medicine pipeline and
- 6mo agoLXEOLexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual MeetingGlobeNewswireNEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced today that
- 7mo agoLXEOLexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational HighlightsGlobeNewswireSUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026 following Type B meeting; study initiation on track for 1H 2026 First CMC Development and Readiness Program (CDRP) meeting
- 8mo agoLXEOLexeo Therapeutics to Participate in the Leerink Global Healthcare ConferenceGlobeNewswireNEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that
- 9mo agoLXEOLexeo Therapeutics to Participate in Upcoming Investor Conferences in FebruaryGlobeNewswireNEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that
- 9mo agoLXEOLexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA TherapeuticsGlobeNewswireNEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced a
- 10mo agoLXEOLexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic CardiomyopathyGlobeNewswireLX2020 generally well tolerated across ten participants with no clinically significant complement activation LX2020 transduction, transcription, and increased protein expression observed across participants with
- 10mo agoLXEOLexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene TherapyGlobeNewswireCollaboration will combine Lexeo expertise in cardiac genetic medicine with Johnson & Johnson's expertise in cardiovascular therapeutics and circulatory technologies, including Impella™ heart pumps Agreement
- 10mo agoLXEOLexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireNEW YORK, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that
- 11mo agoLXEOLexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) ForumGlobeNewswireNEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced plans
- 1y agoLXEOLexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational HighlightsGlobeNewswireFDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier co-primary endpoint assessment, to support a Biologics License Application FDA approved comparability
- 1y agoLXEOMBRXACADGUTSBeyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat ConditionsPR NewswireEquity InsiderNews Commentary – Conventional small molecule approaches have struggled to address genetic defects and complex disease mechanisms,...
- 1y agoLXEOLexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters' Option to Purchase Additional Shares in the Public OfferingGlobeNewswireNEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO) ("Lexeo"), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today
- 1y agoLXEOLexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private PlacementGlobeNewswireNEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that
- 1y agoLXEOLexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireNEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO) (the "Lexeo"), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today
- 1y agoGTBPLXEOANIXTEM+1Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034PR NewswireOhio State researchers recently solved a critical mystery explaining why some cancer immunotherapies fail[1], while a University of Chicago team...
- 1y agoLXEOLexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia CardiomyopathyGlobeNewswireU.S. Food and Drug Administration (FDA) open to pooling data from ongoing Phase I/II studies of LX2006 with pivotal data to support a Biologics License Application (BLA) for Accelerated Approval Interim clinical data
- 1y agoLXEOLexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational HighlightsGlobeNewswireBreakthrough Therapy designation granted for LX2006 based on interim data from Phase I/II trials demonstrating clinically meaningful improvements in cardiac and neurologic measures of Friedreich ataxia LX2006 selected
- 1y agoLXEOLexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich AtaxiaGlobeNewswireBreakthrough Therapy designation based on interim clinical data from Phase I/II trials showing clinically meaningful improvements in cardiac biomarkers and functional measures LX2006 also selected for FDA Chemistry,
- 1y agoLXEOLexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA TherapeuticsGlobeNewswireUp to $40 Million Private Equity Financing into a New Entity Addressing Cardiac Genetic Diseases that Existing AAV Platforms are Unable to Treat Lexeo Contributing Expertise and Know-How in Cardiac Genetic Medicines,
- 1y agoLXEOLexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular DiseasesGlobeNewswireCash runway extended into 2028; capital proceeds to fund operations through potential 2027 efficacy readout for LX2006 in Friedreich ataxia cardiomyopathy Financing led by Frazier Life Sciences and Janus Henderson
- 1y agoLXEOLexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational HighlightsGlobeNewswireAnnounced positive interim data for LX2006 from Phase 1/2 studies in Friederich ataxia (FA) cardiomyopathy; frataxin expression and LVMI improvement exceeded co-primary target thresholds for planned registrational study
- 1y agoLXEOLexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual MeetingGlobeNewswireNEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced today that
- 1y agoLXEOLexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational StudyGlobeNewswireParticipants with abnormal left ventricular mass index (LVMI) at baseline achieved 25% mean reduction in LVMI by 12 months or sooner Clinically meaningful improvements in majority of participants across cardiac
- 1y agoLXEOLexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational HighlightsGlobeNewswireAdditional alignment with FDA on LX2006 planned pivotal study including protein expression co-primary endpoint: based on improvements in LVMI across participants with abnormal LVMI at baseline, frataxin expression to be
- 1y agoLXEOLexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireNEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases, today
- 1y agoLXEOLexeo Therapeutics Appoints Kyle Rasbach as Chief Financial OfficerGlobeNewswireNEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and
- 1y agoABBVLXEOMSCLFTSX:MSCLSatellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024Business WireSatellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases
- 1y agoLXEOLexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial ResultsGlobeNewswireReached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression as co-primary
- 2y agoLXEOLexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) ConferenceGlobeNewswireDose-dependent increase in neuroprotective APOE2 expression in all participants with ongoing durability at 12 months Consistent reductions across CSF tau biomarkers and tau PET in majority of participants LX1001
- 2y agoLXEOLexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 ConferenceGlobeNewswireNEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and
- 2y agoLXEOLexeo Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireNEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and
- 2y agoLXEOLexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational HighlightsGlobeNewswireAnnounced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no treatment-related serious adverse events and demonstrated evidence of
- 2y agoLXEOLexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia CardiomyopathyGlobeNewswireAchieved mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at 18 months in participants with elevated LVMI at baseline >10% reduction in LVMI at 12 months in 75% of
- 2y agoLXEOLexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024GlobeNewswireNEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and
- 2y agoLXEOLexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of DirectorsGlobeNewswireNEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company, today announced the appointment of Tim Van Hauwermeiren, co-founder and Chief Executive
- 2y agoLXEOLexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational HighlightsGlobeNewswireClosed an oversubscribed $95 million equity financing in March with Q1 2024 cash balance of $195.1 million at quarter-end, expected to provide runway into 2027 Completed in-license agreement with Cornell University for
- 2y agoLXEOLexeo Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireNEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and
- 2y agoLXEOLexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia CardiomyopathyGlobeNewswireLexeo Therapeutics gains intellectual property rights including current and future clinical data from ongoing Weill Cornell Medicine investigator-initiated trial of gene therapy candidate AAVrh.10hFXN (LX2006) to support
- 2y agoLXEOLexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia CardiomyopathyGlobeNewswireNEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and
- 2y agoLXEOLexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity FinancingGlobeNewswireNEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and